Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 20 of 718 for:    "Migraine Disorders"

Use Of GW274150 In The Prophylactic Treatment Of Migraine

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: October 19, 2005
Last updated: May 5, 2016
Last verified: September 2015
Nitric oxide (NO) is likely to be involved in the development of migraine headache. Nitric oxide synthase (NOS) is an important chemical involved in the production of NO. Reduction of NOS, and therefore NO, may be an effective technique for the prevention of migraine headache. GW274150 is a highly selective inhibitor of NOS and offers the potential of anti-inflammatory activity in migraine through a novel mechanism of action. The intent of this study is to investigate the safety and efficacy of GW274150 for the prophylactic treatment of migraine headache.

Condition Intervention Phase
Migraine Disorders
Drug: GW274150
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Multicentre, Two-part, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Tolerability and Pharmacokinetics of the iNOS Inhibitor GW274150 Administered up to 120mg Daily for 12 Weeks in the Prophylactic Treatment of Migraine.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Occurrence of a migraine headache day on each day during the 4-week baseline period and the 12-week treatment period. [ Time Frame: 12 Weeks ]

Secondary Outcome Measures:
  • Change from baseline in the number of migraine headache days, migraine attacks, mean peak migraine pain severity and mean migraine headache duration for each 4 week treatment period and over the entire treatment period. [ Time Frame: 12 Weeks ]

Enrollment: 430
Study Start Date: October 2005
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
GW274150 - 5mg or 30mg
Drug: GW274150
The tablets used in this study will contain either 5mg or 30mg of GW274150
Other: Placebo
Placebo to Match GW274150
Placebo Comparator: Arm 2
Placebo to match GW274150
Drug: GW274150
The tablets used in this study will contain either 5mg or 30mg of GW274150
Other: Placebo
Placebo to Match GW274150


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Suffering from migraine with or without aura.
  • Migraine for at least one year, and the age of onset was prior to 50 years.
  • Consistent migraine headache over time and has had at least 3 migraine headache attacks but less than 15 days with headache (migraine or non-migraine) per month in each of the three months prior to the Screening Visit and maintains this requirement during the baseline period.
  • Able to distinguish migraine headache attacks as discreet attacks from other headaches (i.e. tension-type headaches).
  • No clinically significant abnormality identified on the medical or laboratory evaluation. A subject with a clinical abnormality or laboratory parameters outside the reference range may be included only if the doctor considers that the finding will not introduce additional risk factors and will not interfere with the study procedures.
  • Written informed consent prior to entry into the study.
  • Females who are: a) non-childbearing potential or, b) of child-bearing potential, has a negative pregnancy test at screen, and is taken adequate contraceptive measures.

Exclusion Criteria:

  • As a result of the medical interview, physical examination or screening investigations, that the doctor considers the subject unfit for the study.
  • Headache for 15 days per month or greater in any of the three months (90 days) preceding the Screening Visit.
  • History of alcohol, substance or drug abuse within the last year.
  • Taken a migraine prophylactic medication within 1 month of the Screening Visit.
  • Uses an opiate as first line acute treatment for migraine attacks.
  • History of ergotamine, triptan, opioid, or combination medication intake on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months.
  • History of simple analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months.
  • Failed two or more adequate treatments of migraine prophylaxis, where failure is defined as a lack of efficacy with a treatment duration of at least 8 weeks or withdrawal of treatment due to treatment intolerance.
  • Uncontrolled hypertension at the Screening Visit, defined as systolic blood pressure >140mmHg or diastolic blood pressure >90mmHg.
  • Taking cyclosporine and/or aminoglycosides.
  • Evidence of renal impairment - calculated creatinine clearance <60ml/min or clinically relevant finding on urinalysis.
  • History of drug or other allergy which, in the opinion of the doctor, makes the subject unsuitable for participation in the study.
  • Concurrently participating in another clinical study or investigational drug trial or has participated within the previous 3 months or is planning to participate in another drug or device study at any time during this study (screening through follow-up) or has had previous exposure to GW274150 in Part 1 of the study.
  • Felt to be at risk of non-compliance (for taking study medication or for completing the electronic diary (e-diary)), in the doctor's opinion.
  • Pregnant or nursing women.
  • History of, or risk factors for, HIV, Hepatitis B and Hepatitis C.
  • Past or present disease, which as judged by the doctor, may affect the outcome of this study. These diseases include, but are not limited to history of liver or renal disease in the 6 months prior to screening.
  • Clinically significant abnormalities in safety laboratory analysis at the Screening Visit, particularly any abnormal liver or pancreatic function test at the Screening Visit.
  • Not covered by social security.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00242866

  Show 62 Study Locations
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00242866     History of Changes
Other Study ID Numbers: NOS103325
Study First Received: October 19, 2005
Last Updated: May 5, 2016

Keywords provided by GlaxoSmithKline:
without aura
Nitric Oxide
with aura
Quality of Life

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on April 27, 2017